Terms: = Lymphoma AND JAK2, ENSG00000096968, O60674, JTK10, 3717 AND Clinical Outcome
8 results:
1. DLBCL with amplification of jak2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation.
Xue X; Huang W; Qiu T; Guo L; Ying J; Lv N
BMC Cancer; 2020 Aug; 20(1):816. PubMed ID: 32854650
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic gene alterations and clonal changes in childhood B-ALL.
Erbilgin Y; Firtina S; Mercan S; Hatirnaz Ng O; Karaman S; Tasar O; Karakas Z; Celkan TT; Zengin E; Sarper N; Yildirmak ZY; Sisko S; Ozbek U; Sayitoglu M
Leuk Res; 2019 Aug; 83():106159. PubMed ID: 31228652
[TBL] [Abstract] [Full Text] [Related]
3. Promoter methylation and expression of SOCS3 affect the clinical outcome of pediatric acute lymphoblastic leukemia by JAK/STAT pathway.
Liu K; Wu Z; Chu J; Yang L; Wang N
Biomed Pharmacother; 2019 Jul; 115():108913. PubMed ID: 31054507
[TBL] [Abstract] [Full Text] [Related]
4. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.
Roberts KG; Reshmi SC; Harvey RC; Chen IM; Patel K; Stonerock E; Jenkins H; Dai Y; Valentine M; Gu Z; Zhao Y; Zhang J; Payne-Turner D; Devidas M; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Mattano LA; Maloney KW; Carroll WL; Loh ML; Willman CL; Gastier-Foster JM; Mullighan CG; Hunger SP
Blood; 2018 Aug; 132(8):815-824. PubMed ID: 29997224
[TBL] [Abstract] [Full Text] [Related]
5. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.
Sato T; Tran TH; Peck AR; Girondo MA; Liu C; Goodman CR; Neilson LM; Freydin B; Chervoneva I; Hyslop T; Kovatich AJ; Hooke JA; Shriver CD; Fuchs SY; Rui H
Oncogene; 2014 Apr; 33(17):2215-24. PubMed ID: 23708665
[TBL] [Abstract] [Full Text] [Related]
6. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices.
Tefferi A
Leuk Lymphoma; 2010 Apr; 51(4):576-82. PubMed ID: 20214447
[TBL] [Abstract] [Full Text] [Related]
7. Regulation of jak2 by miR-135a: prognostic impact in classic Hodgkin lymphoma.
Navarro A; Diaz T; Martinez A; Gaya A; Pons A; Gel B; Codony C; Ferrer G; Martinez C; Montserrat E; Monzo M
Blood; 2009 Oct; 114(14):2945-51. PubMed ID: 19666866
[TBL] [Abstract] [Full Text] [Related]
8. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and jak2 mutations on clinical outcome.
Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
[TBL] [Abstract] [Full Text] [Related]
